Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging.
bone metastasis
castration-resistant prostate cancer
flare phenomenon
imaging
systemic treatment
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
08
2020
accepted:
17
12
2020
entrez:
12
3
2021
pubmed:
13
3
2021
medline:
13
3
2021
Statut:
epublish
Résumé
Over the years, an increasing proportion of metastatic prostate cancer patients has been found to experience an initial bone flare phenomenon under both standard therapies (androgen deprivation therapy, chemotherapy, radiotherapy, abiraterone, enzalutamide) and novel agents (immunotherapy, bone-targeting radioisotopes). The underlying biological mechanisms of the flare phenomenon are still elusive and need further clarification, particularly in relation to different types of treatment and their treatment response assessment. Flare phenomenon is often underestimated and, in some cases, can negatively affect clinical outcome. In cases with suspected bone flare, the treatment should be continued for a minimum of 12 more weeks before further decisions about efficacy can be taken. Physicians and patients should be aware of this effect to avoid unwarranted anxiety and inadequate early discontinuation of treatment. This review aims at highlighting new evidence on flare phenomenon arising after the introduction of new drugs extending across the biochemical, radiographic and clinical spectrum of the disease.
Identifiants
pubmed: 33708265
doi: 10.1177/1758835920987654
pii: 10.1177_1758835920987654
pmc: PMC7907710
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1758835920987654Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: VC has received speaker honoraria or travel support from Astellas, Janssen-Cilag and Sanofi-Aventis, and has received consulting fee from Bayer and Janssen-Cilag. PM has/had a consultant/advisory role for BMS, Roche, Genentech, MSD, Novartis, Amgen, Merck Serono, Pierre Fabre, and Incyte. UDG has served as consultant/advisory board member for Astellas, Bayer, BMS, Ipsen, Janssen, Merck, Pfizer and Sanofi; has received travel support from BMS, Ipsen, Janssen and Pfizer; and has received research funding from AstraZeneca, Roche and Sanofi (Inst). No potential conflicts of interest were disclosed by the other authors.
Références
J Nucl Med. 2020 Oct;61(10):1476-1483
pubmed: 32111687
J Clin Oncol. 2015 Apr 20;33(12):1356-63
pubmed: 25624432
Nature. 2015 Jul 16;523(7560):347-51
pubmed: 26030522
Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2189-2194
pubmed: 28801787
Clin Nucl Med. 2016 Jul;41(7):515-21
pubmed: 26975008
J Clin Oncol. 2004 Feb 1;22(3):537-56
pubmed: 14752077
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
AJR Am J Roentgenol. 1984 Apr;142(4):773-6
pubmed: 6230903
Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1576-1577
pubmed: 31011768
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
Oncol Lett. 2015 Dec;10(6):3585-3590
pubmed: 26788174
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Front Med (Lausanne). 2020 Jan 22;6:342
pubmed: 32039220
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Eur Radiol. 2019 Aug;29(8):4503-4513
pubmed: 30413957
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Clin Genitourin Cancer. 2018 Oct;16(5):349-354
pubmed: 29778323
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1276-83
pubmed: 25808631
Clin Genitourin Cancer. 2016 Oct;14(5):373-380.e2
pubmed: 27053499
J Nucl Med. 1988 Aug;29(8):1354-9
pubmed: 3261330
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Hum Pathol. 2000 May;31(5):578-83
pubmed: 10836297
Anticancer Res. 2019 May;39(5):2553-2559
pubmed: 31092452
Prostate Cancer Prostatic Dis. 2019 May;22(2):324-330
pubmed: 30413807
Eur Urol. 2015 Jan;67(1):53-60
pubmed: 24882673
J Urol. 1999 Feb;161(2):608-9
pubmed: 9915462
Prostate. 2017 Jun;77(9):1012-1019
pubmed: 28429372
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):289-293
pubmed: 28244493
Br J Cancer. 2009 Oct 20;101(8):1225-32
pubmed: 19789531
J Cancer Res Clin Oncol. 2014 Oct;140(10):1769-76
pubmed: 24858569
Clin Genitourin Cancer. 2017 Apr;15(2):320-325
pubmed: 27601278
Br J Cancer. 2020 Sep;123(6):982-987
pubmed: 32669676
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Oncotarget. 2014 Dec 15;5(23):12448-58
pubmed: 25504434
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Clin Cancer Res. 2011 Jul 15;17(14):4854-61
pubmed: 21632851
Eur Urol. 2014 Feb;65(2):467-79
pubmed: 24321502
Clin Cancer Res. 2017 Nov 15;23(22):6764-6770
pubmed: 28663235
JAMA Oncol. 2020 Feb 1;6(2):217-225
pubmed: 31830211
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Cancer. 2003 Feb 1;97(3 Suppl):739-47
pubmed: 12548571
Oncotarget. 2015 May 20;6(14):12520-8
pubmed: 25904051
Pract Radiat Oncol. 2017 Jan - Feb;7(1):4-12
pubmed: 27663933
J Nucl Med. 2017 Aug;58(8):1196-1200
pubmed: 28663195
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):665-673
pubmed: 31879814
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1934-40
pubmed: 18649080
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2256-2263
pubmed: 29785515
Clin Cancer Res. 2005 Jun 15;11(12):4451-9
pubmed: 15958630
Eur Urol Oncol. 2018 May;1(1):78-82
pubmed: 31100231
Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):7-13
pubmed: 20697891
Clin Nucl Med. 1990 Jul;15(7):485-7
pubmed: 2116949
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Clin Genitourin Cancer. 2015 Feb;13(1):39-43
pubmed: 24999168
BMC Cancer. 2015 May 07;15:371
pubmed: 25948240
Ann Nucl Med. 2019 Dec;33(12):945-954
pubmed: 31587172
Lancet Oncol. 2015 Nov;16(15):1463-1472
pubmed: 26489389
Acta Radiol. 2011 Jun 1;52(5):557-61
pubmed: 21498309
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):92-101
pubmed: 27557844